Metastatic carcinoma
disease diseaseOn this page
Summary
Metastatic carcinoma (MONDO:0024879) is a cancer and 8 clinical trials. Top therapeutic interventions include vistusertib. A subtype of secondary carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 8
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | metastatic carcinoma |
| Mondo ID | MONDO:0024879 |
| ICD-11 | 553023050 |
| NCIT | C3482 |
| UMLS | C1384494 |
| MedGen | 235141 |
| Is cancer (heuristic) | yes |
Also known as: metastatic carcinoma
Disease family
An umbrella term covering 4 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › secondary carcinoma › metastatic carcinoma
Subtypes (4): Krukenberg carcinoma, metastatic carcinoma in the adrenal medulla, metastatic carcinoma in the bone, metastatic squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 8.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| Not specified | 3 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01320241 | PHASE2 | COMPLETED | Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture |
| NCT01469598 | PHASE2 | COMPLETED | Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer |
| NCT02605811 | PHASE2 | UNKNOWN | Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer |
| NCT02730923 | PHASE1/PHASE2 | UNKNOWN | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) |
| NCT02192346 | PHASE1 | COMPLETED | α-TEA in Advanced Cancer |
| NCT02960282 | Not specified | TERMINATED | Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy |
| NCT04376502 | Not specified | TERMINATED | Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma. |
| NCT04939246 | Not specified | COMPLETED | Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| VISTUSERTIB | 2 | 1 |
| CHEMBL1510899 | 0 | 1 |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.